[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"major-adverse-cardiac-events\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:major-adverse-cardiac-events":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,72,99,125,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100635602","phase-4-major-adverse-cardiovascular-events-mace-in-rheumatoid-arthritis-patient-with-moderate-to-severe-disease-activity-treated-with-tofacitinib-and-statins-vs-tnf-inhibitors-tofstat-clinical-trial-100635602",false,"NCT07554820","Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL","TOFSTAT","Inclusion Criteria:\n\n* • RA diagnosis with moderate to severe disease activity, based on DAS-28 despite on \\> 2 conventional DMARDs.\n\n  * One or more CVD risk factors, such as hypertension, diabetes, smoking, high cholesterol, etc.\n  * Age 50 or older.\n\nExclusion Criteria:\n\n* Known contraindications to statins.\n\n  * History of major adverse CV events (e.g., recent myocardial infarction or stroke).\n  * Pregnancy or breastfeeding.","ALL","50 Years","85 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The rationale of our study is to observe the incidence of MACE in RA patients treated with tofacitinib along with statins with one or more cardiovascular disease risks.\n\nPRIMARY OBJECTIVE\n\n* To determine the incidence of MACE in Rheumatoid Arthritis patients with moderate to high disease activity and with one or more cardiovascular disease risks, which are non-responsive to standard conventional DMARDs (cDMARDs) treatment and are prescribed Tofacitinib 5 mg twice daily along with statin 20 mg daily versus TNF Inhibitors.\n* The study aim to compare MACE in RA patients treated with tofacitinib and statin versus TNF inhibitors.",[27,28],"Rheumatoid Arthritis","Major Adverse Cardiac Events",[30],"rheumatoid arthritis, Major adverse cardiac event, tofacitinib","RECRUITING","2026-04-21",{"date":34,"type":35},"2026-04-28","ACTUAL",{"date":37,"type":35},"2025-12-06",{"date":39,"type":21},"2026-09-30",{"name":41,"class":42},"Shaikh Zayed Hospital, Lahore","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100531803","impact-of-assessment-and-management-of-comorbidities-in-internal-medicine-on-cardiovascular-risk-100531803","NCT06204549","Impact of Assessment and Management of Comorbidities in Internal Medicine on Cardiovascular Risk","Impact du Bilan et de la Prise en Charge Des comorbidités en médecine Interne Sur le Risque Cardiovasculaire","COMMEDCARDIO","Inclusion Criteria:\n\n* High-Risk Cardiovascular patients either receiving:\n\n  * Primary prevention because they have never had a cardiovascular event but have several cardiovascular risk factors such as high blood pressure particularly resistant, metabolic syndrome, diabetes , dyslipidemia, metabolic steatosis\n  * Or secondary prevention because they have already had a major cardiovascular event such as ischemic heart disease, heart failure\n* Aged 18 and over\n* Patient benefiting from comorbidities assessment during their planned hospitalization in the internal medicine department.\n\nExclusion Criteria:\n\n* Patient refusal\n* Subject not registered in social security system\n* Pregnant or breastfeeding woman\n* Patient unable to give their informed consent, protected adult, vulnerable people\n* Subject deprived of liberty by judicial or administrative decision","18 Years",{"count":54,"type":21},70,[56],"NA","The aim of assessing and managing cardiovascular risk is to avoid, limit or delay cardiovascular morbidity and mortality. Planned internal medicine hospitalization is developed around the management of cardiovascular risk in patients at high cardiovascular risk, whether in primary prevention or secondary prevention.\n\nDuring planned hospitalization, patients benefit from comprehensive, personalized and adapted care for their comorbidities and their CVRF (cardiovascular risk factors).\n\nThis study will make it possible to evaluate this overall course of multidisciplinary management of comorbidities of patients at high cardiovascular risk.",[59,28],"Adverse Cardiac Event",[61,62],"Cardiovascular Risk","Comorbidities","2025-09-24",{"date":65,"type":35},"2025-09-30",{"date":67,"type":35},"2024-05-21",{"date":69,"type":21},"2027-11-21",{"name":71,"class":42},"University Hospital, Montpellier",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":43},"100597796","tte-improves-clinical-management-of-stable-chest-pain-100597796","NCT07063147","TTE Improves Clinical Management of Stable Chest Pain","Improving the Clinical Management of Stable Chest Pain Based on Imaging: a Registry of Transthorcic Echocardiography","TICM-SCP","Inclusion Criteria:\n\n* symptomatic patients with SCP suspected of obstructive CAD.\n* referred for TTE for the assessment of SCP.\n* ≥18 years of age.\n* signed informed consent.\n\nExclusion Criteria:\n\n* acute coronary syndromes\n* previous CAD or coronary revascularization\n* nonsinus rhythm\n* cardiomyopathy, valvular disease, congenital heart disease or left cardiac insufficiency because of other reasons",{"count":81,"type":21},50000,"10 Years","OBSERVATIONAL","The investigator aims to prospectively enroll patients who were referred for transthorcic echocardiography (TTE) for the assessment of stable chest pain (SCP) suspected of obstructive coronary artery disease (CAD). All patients underwent TTE according to established guidelines and local institutional protocols. This study will determine if TTE-based imaging evaluation can provide more informaton to improve clinical management for SCP, including fewer MACE and better decision-making of downstream investigations and therapeutic interventions.",[86,87,88,28,89],"Transthorcic Echocardiography","Stable Angina Pectoris","Coronary Artery Disease","Invasive Coronary Angiography","2025-07-15",{"date":92,"type":35},"2025-07-18",{"date":94,"type":35},"2025-01-01",{"date":96,"type":21},"2040-12-31",{"name":98,"class":42},"Tianjin Chest Hospital",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":43},"100524414","phase-4-low-dose-versus-standard-dose-rivaroxaban-in-elderly-patients-with-atrial-fibrillation-100524414","NCT06108414","Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation","The Efficacy and Safety of Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation","Inclusion criteria:\n\n* Age ≥70 years\n* Patients with atrial fibrillation (atrial fibrillation rhythm of at least 30 seconds duration recorded by ECG or Holter within 1 year)\n* CHA2DS2-VASc score ≥2 in men and ≥3 in women\n* Able to cooperate in signing ICFs\n\nExclusion criteria：\n\n* Moderate-to-severe mitral stenosis, or prior mechanical valve replacement surgery, or unresected atrial myxoma, or known left ventricular thrombus\n* Prior biological valve replacement or valve repair surgery within 6 months\n* Left ventricular assist device implantation status\n* Severe stroke event within 3 months or any stroke within 14 days Major stroke events were defined as those with a Modified Rankin Scale score of 3-5.\n\nScore 3: moderately disabled, requiring some assistance but walking without assistance; Score 4: severe disability, unable to walk independently, unable to meet their own needs without the help of others; Score 5: severe disability, bedridden, incontinent, requiring ongoing care and attention\n\n* Transient ischemic attack (TIA) occurred within 3 days\n* Transient atrial fibrillation due to reversible triggers (e.g., after cardiac surgery, pulmonary embolism, untreated hyperthyroidism)\n* Prior or planning to undergo atrial fibrillation catheter ablation, drug cardioversion, electroconversion, or major surgery in 3 months; Prior catheter or surgical ablation \\> 3 months without atrial fibrillation electrocardiogram records\n* Prior or planning to undergo left atrial appendage occlusion\n* Active infective endocarditis\n* High or increasing risk for bleeding i. Traumatic surgery that has been completed within the last 3 months or is planned within the next 3 months ii. Previous severe intracranial, intraocular, spinal cord, retroperitoneal, or nontraumatic intra-articular hemorrhage.\n\niii. Gastrointestinal bleeding within the past year iv. Symptomatic or gastroscopic peptic ulcer within the last month v. Hemorrhagic constitution or coagulopathy vi. Difficult-controlled hypertension (180mm Hg systolic and\u002For 100 mm Hg diastolic)\n\n* Severe renal impairment (estimated creatinine clearance ≤ 15 mL\u002Fmin)\n* Active liver disease\n\nIncluding but not limited to:\n\ni. Persistent ALT, AST \\> 2×ULN; ii. TBil \\> 1.5×ULN; iii. Known active hepatitis A, B or C; iv. Cirrhosis\n\n* Hemoglobin level \\\u003C100g\u002FL or thrombocytopenia count \\\u003C100 × 10\\^9\u002FL\n* Having conditions warrant standard-dose or low-dose anticoagulation treatment (non-AF, such as VTE)\n* Having conditions warrant warfarin anticoagulation treatment\n* Daily dose of aspirin \\>100mg\n* Having received dual antiplatelet therapy or intravenous antiplatelet drugs within 5 days (note: P2Y12 receptor antagonist alone or ≤ 100mg aspirin alone can be enrolled)\n* Having received fibrinolysis treatment in 10 days or planning to use fibrinolytic drugs\n* Having conditions warrant the following medications: CYP3A4 and P-gp inhibitors (itraconazole, ketoconazole, voriconazole, posaconazole, clarithromycin, erythromycin, fluconazole, ritonavir, dronedarone, etc.), selective serotonin reuptake inhibitors (SSRI)\u002Fserotonin norepinephrine reuptake inhibitors (SNRI) drugs (fluoxetine, paroxelin, etc.) CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's wort, etc.), long-term use of NSAIDs\n* Having allergic or adverse reactions to any excipients (including but not limited to lactose, starch, etc.) in rivaroxaban tablets, including but not limited to hereditary lactose or galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, etc.\n* Having diagnosed with malignant tumors within 6 months, or receiving radiotherapy\u002Fchemotherapy, with an expected lifespan of no more than 3 years\n* Antiphospholipid syndrome\n* Having been enrolled in another interventional clinical trial within the past 30 days or at the same time\n* Mental disorders, communication barriers, cognitive impairment, or other serious illnesses that may affect the participation in this study\n* Known poor adherence to study follow-up or taking study drugs\n* Other conditions deemed by the investigator to be inappropriate for enrollment","70 Years",{"count":108,"type":21},4374,[24],"To evaluate the efficacy and safety of low-dose versus standard-dose rivaroxaban anticoagulation therapy in elderly patients with atrial fibrillation.",[112,113,114,28],"Atrial Fibrillation","Anticoagulant Adverse Reaction","Stroke","2024-09-11",{"date":117,"type":35},"2024-09-19",{"date":119,"type":35},"2024-09-01",{"date":121,"type":21},"2027-12-31",{"name":123,"class":124},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100545787","study-on-the-serum-metabolic-markers-and-early-complications-after-allo-hsct-cohort-study-100545787","NCT06386445","Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study","Study on the Serum Metabolic Markers and Early Complications After Allogeneic Hematopoietic Stem Cell Transplantation in Hemaotological Diseases： Cohort Study","Inclusion Criteria:\n\n* Age ≤ 65 years old;\n\nGender unlimited;\n\nNormal heart and kidney function before transplantation;\n\nPatients with indications for allogeneic hematopoietic stem cell transplantation.\n\nExclusion Criteria:\n\n* CREA or BUN higher than the normal upper limit value before transplantation;\n\nIndividuals with a history of arrhythmia, heart failure, or PCI stent implantation prior to transplantation;\n\nPatients with mental illness;\n\nThose who are unwilling to sign informed consent.","0 Years","65 Years",{"count":135,"type":21},500,"This study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region. All patients will be followed up at the outpatient clinic once a week after transplantation until 100 days after transplantation to observe the presence of acute graft versus host disease, acute kidney damage, and major cardiovascular adverse events. Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks，4 weeks，8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.The primary objective is to explore the serum metabolic markers of acute graft versus host disease，acute kidney injury, and major adverse cardiac events within 100 days after transplantation，the secondary objective is to observe the high-risk factors for early complications.",[138,139,140,28],"Stem Cell Transplant Complications","Acute Graft Versus Host Disease","Acute Kidney Injury","NOT_YET_RECRUITING","2024-04-23",{"date":144,"type":35},"2024-04-26",{"date":146,"type":21},"2024-05-01",{"date":148,"type":21},"2026-12-31",{"name":150,"class":42},"First Affiliated Hospital Xi'an Jiaotong University",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":158,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":4},"100518993","novel-cardiovascular-biomarkers-in-patients-with-kidney-disease-100518993","NCT06037759","Novel Cardiovascular Biomarkers in Patients With Kidney Disease","CBKD","Inclusion Criteria:\n\nPatients aged≥45 years (or ≥18 with a history of diabetes). b. Cases: Incident haemodialysis patients c. A comparative arm of peritoneal dialysis patients and CKD 3-4 (not on dialysis) with hypertension as a key risk factor for CVD.\n\nd. Capable of understanding the purpose and risks of the study, fully informed, and given informed consent.\n\nExclusion Criteria:\n\n1. Patients with pre-existing heart disease will be excluded.\n2. Patients with active cancer.",true,{"count":160,"type":21},100,"Chronic kidney disease (CKD) is a long-term condition where the kidneys do not work as well as they should. End-stage kidney failure (ESKD) is the final, irreparable stage of chronic kidney disease (CKD), where kidney function has worsened, so the kidneys can no longer function independently.\n\nAt this stage, dialysis is required to remove waste products and excess fluid from the blood. There are two types of dialysis. In haemodialysis (HD), blood is pumped out of the body to an artificial kidney machine and returned to the body by tubes that connect a person to the machine. In peritoneal dialysis (PD), the inside lining of the belly acts as a natural filter. PD has the advantage of being gentler on the heart. HD causes significant stress to the heart by reducing the blood flow to the heart muscle, resulting in heart failure, irregular rhythms, and eventually sudden heart death. A large observational study showed that HD patients had 48% worse survival in the first two years than PD patients.\n\nSeveral molecules ('biomarkers') can be detected in blood and inform doctors of heart damage. Studying the form and function of proteins (Proteomics), including how they work and interact with each other inside cells in patients, could help identify the onset of heart problems. HD patients are also prone to body fat changes (cholesterol\u002Flipids). Due to high cholesterol, there is build-up on the walls of arteries, causing their hardening. In HD patients, this process is faster due to abnormalities in lipid structure. Therefore, studying the heart biomarkers, protein, and lipid makeup of HD patients may help to find people at substantial risk of heart and vascular problems and if they are likely to become unwell due to these heart problems.",[163,28],"Haemodialysis Complication",[165,166,167,168,28],"Chronic Kidney Disease","End Stage Kidney Disease","Haemodialysis","Biomarkers","2023-09-14",{"date":171,"type":35},"2023-09-18",{"date":173,"type":21},"2023-11-01",{"date":175,"type":21},"2026-11-01",{"name":177,"class":124},"Liverpool University Hospitals NHS Foundation Trust"]